Literature DB >> 20137937

Evaluation of a 3-amino-8-azabicyclo[3.2.1]octane replacement in the CCR5 antagonist maraviroc.

Rémy C Lemoine1, Ann C Petersen, Lina Setti, Thomas Baldinger, Jutta Wanner, Andreas Jekle, Gabrielle Heilek, André deRosier, Changhua Ji, David M Rotstein.   

Abstract

The bicyclic 5-amino-3-azabicyclo[3.3.0]octanes were shown to be effective replacements for the 3-amino-8-azabicyclo[3.2.1]octane found in the CCR5 antagonist maraviroc. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20137937     DOI： 10.1016/j.bmcl.2010.01.080

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  7 in total

Review 1.  Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications.

Authors:  Guoyan G Xu; Jia Guo; Yuntao Wu
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

Review 2.  CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV.

Authors:  Michelle B Kim; Kyle E Giesler; Yesim A Tahirovic; Valarie M Truax; Dennis C Liotta; Lawrence J Wilson
Journal:  Expert Opin Investig Drugs       Date:  2016-12       Impact factor: 6.206

3.  Design and synthesis of a bivalent ligand to explore the putative heterodimerization of the mu opioid receptor and the chemokine receptor CCR5.

Authors:  Yunyun Yuan; Christopher K Arnatt; Guo Li; Kendra M Haney; Derong Ding; Joanna C Jacob; Dana E Selley; Yan Zhang
Journal:  Org Biomol Chem       Date:  2012-02-22       Impact factor: 3.876

4.  Discovery of VU6028418: A Highly Selective and Orally Bioavailable M4 Muscarinic Acetylcholine Receptor Antagonist.

Authors:  Matthew Spock; Trever R Carter; Katrina A Bollinger; Changho Han; Logan A Baker; Alice L Rodriguez; Li Peng; Jonathan W Dickerson; Aidong Qi; Jerri M Rook; Jordan C O'Neill; Katherine J Watson; Sichen Chang; Thomas M Bridges; Julie L Engers; Darren W Engers; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Aaron M Bender
Journal:  ACS Med Chem Lett       Date:  2021-08-02       Impact factor: 4.632

5.  A Bivalent Ligand Targeting the Putative Mu Opioid Receptor and Chemokine Receptor CCR5 Heterodimers: Binding Affinity versus Functional Activities.

Authors:  Yunyun Yuan; Christopher K Arnatt; Nazira El-Hage; Seth M Dever; Joanna C Jacob; Dana E Selley; Kurt F Hauser; Yan Zhang
Journal:  Medchemcomm       Date:  2013-05-01       Impact factor: 3.597

6.  Asymmetric Synthesis of γ-Amino Alcohols by Copper-Catalyzed Hydroamination.

Authors:  Saki Ichikawa; Stephen L Buchwald
Journal:  Org Lett       Date:  2019-10-18       Impact factor: 6.005

7.  Discovery of Novel CCR5 Ligands as Anticolorectal Cancer Agents by Sequential Virtual Screening.

Authors:  Mariam A El-Zohairy; Darius P Zlotos; Martin R Berger; Hassan H Adwan; Yasmine M Mandour
Journal:  ACS Omega       Date:  2021-04-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.